Lilly's oral GLP-1 Foundayo (orforglipron) delivered superior A1C control and weight loss in three pivotal type 2 diabetes trials

Lilly's Foundayo (orforglipron), the only oral GLP-1 taken without food or water restrictions, was associated…

Eli Lilly's Foundayo, an oral GLP-1 without food/water restrictions, achieved 14.4% weight loss in perimenopausal and 14.1% postmenopausal women. The unrestricted format and efficacy reshape menopausal health management, affecting employee wellness programs and corporate benefit design.